Does lapatinib work against HER2-negative breast cancers?

Ingrid A. Mayer; Carlos L. Arteaga

doi:10.1158/1078-0432.CCR-09-3223

Does lapatinib work against HER2-negative breast cancers?

Ingrid A. Mayer, Carlos L. Arteaga

Research output: Contribution to journal › Comment/debate › peer-review

15 Scopus citations

Abstract

Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.

Original language	English (US)
Pages (from-to)	1355-1357
Number of pages	3
Journal	Clinical Cancer Research
Volume	16
Issue number	5
DOIs	https://doi.org/10.1158/1078-0432.CCR-09-3223
State	Published - Mar 1 2010

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-09-3223

Cite this

@article{117ff6ae0991468d83fdde38510b88c5,

title = "Does lapatinib work against HER2-negative breast cancers?",

abstract = "Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.",

author = "Mayer, {Ingrid A.} and Arteaga, {Carlos L.}",

year = "2010",

month = mar,

day = "1",

doi = "10.1158/1078-0432.CCR-09-3223",

language = "English (US)",

volume = "16",

pages = "1355--1357",

journal = "Clinical Cancer Research",

issn = "1078-0432",